In CLL, spectral flow cytometry analysis of PB from 10 ibrutinib‐responsive and eight relapsing patients showed an increase of proliferating CD8 T cells as well as in CD4 TFH cells in relapsed patients [28]. This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.